Chromadex CORP Form 4 insider transactions

Carlos Luis Lopez, SVP and General Counsel of Niagen Bioscience, Inc., acquired 2,314 shares of common stock through the company's Employee Stock Purchase Plan.

Niagen Bioscience, Inc. (NAGE) Chief Financial Officer Pamir Ozan acquired shares through the company's Employee Stock Purchase Plan.

Robert N. Fried, CEO and Director of Niagen Bioscience, Inc., reported the acquisition of 1,106 shares of common stock on June 30, 2026.

Niagen Bioscience, Inc. reports a Form 4 filing detailing the acquisition of stock options by Director Wendy Yu Wing Tak.

Director Gary Ng acquired stock options for 31,746 shares of Niagen Bioscience (NAGE) on June 24, 2026, with a vesting date of June 24, 2027.

Ann Cohen, a Director at Niagen Bioscience, Inc., acquired stock options for 31,746 shares of common stock.

Director Patrick Kristin of Niagen Bioscience, Inc. acquired stock options, indicating a potential future investment in the company.

Hamed Shahbazi, a Director at Niagen Bioscience, Inc., acquired stock options on June 24, 2026, as detailed in a recent SEC Form 4 filing.

Director Steven D. Rubin acquired stock options for 31,746 shares of Niagen Bioscience, Inc. (NAGE) on June 24, 2026.

Frank L. Jaksch Jr., Director at Niagen Bioscience, Inc., acquired 31,746 stock options with an exercise price of $3.45.

Robert N. Fried, CEO of Niagen Bioscience, Inc., acquired 20,000 shares of common stock through the exercise of stock options.

Niagen Bioscience's SVP and General Counsel, Carlos Luis Lopez, was granted 41,420 employee stock options with an exercise price of $4.94.

Niagen Bioscience's Chief Financial Officer, Ozan Pamir, was granted 62,131 employee stock options with an exercise price of $4.94, vesting over four years.

Niagen Bioscience CEO Robert Fried was granted 503,937 employee stock options with an exercise price of $4.94, vesting annually over four years.

Niagen Bioscience's CFO, Ozan Pamir, acquired common stock directly and indirectly through a pre-arranged trading plan.

Hamed Shahbazi, a Director at Niagen Bioscience, Inc., was granted 20,000 stock options with an exercise price of $14.13, which will fully vest on June 24, 2026.

Niagen Bioscience, Inc. Director Wendy Yu was granted 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Kristin Patrick, a Director at Niagen Bioscience, Inc., has acquired 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Steven D. Rubin, a Director and 10% Owner of Niagen Bioscience, Inc., was granted 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Ng Wang Yu Gary, a Director and 10% owner of Niagen Bioscience, Inc., has acquired 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Niagen Bioscience, Inc. Director Ann Cohen was granted 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Frank L. Jaksch Jr., a Director and 10% Owner of Niagen Bioscience, Inc., has acquired 20,000 stock options with an exercise price of $14.13, vesting fully by June 24, 2026.

Robert N. Fried, CEO of Niagen Bioscience, exercised stock options for 66,667 shares of common stock at $3.3 per share on April 9, 2025.

Carlos Luis Lopez, SVP and General Counsel of ChromaDex Corp., reports the purchase of 273 shares of common stock at $7.86 per share on March 7, 2025.

ChromaDex Corp. CEO Robert N. Fried was granted 1,518,600 performance stock units (PSUs) on February 25, 2025, which vest upon achieving specific stock price targets and continued employment.

Carlos Luis Lopez, SVP and General Counsel of ChromaDex Corp., reports the acquisition of stock options.

ChromaDex Corp. CFO Pamir Ozan reported the acquisition of employee stock options on February 12, 2025.

ChromaDex Corp. CEO Robert N. Fried reports acquisition of employee stock options.

A ChromaDex director, Frank L. Jaksch Jr., exercised stock options and sold a portion of the acquired shares to cover costs and taxes.

ChromaDex's Chief Financial Officer, Ozan Pamir, acquired 2,907 shares of common stock at an average price of $7.36 on November 22, 2024.